Navigation Links
Quest Diagnostics Completes Acquisition of Clinical Laboratory Partners' Outreach Laboratory Service Business in Connecticut

MADISON, N.J. and HARTFORD, Conn., Feb. 29, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the outreach laboratory service business of Clinical Laboratory Partners (CLP), a wholly-owned subsidiary of Hartford HealthCare (HHC). HHC is an integrated health care system with five hospitals in Connecticut. Financial terms were not disclosed.

With the acquisition, people and providers in Connecticut will have broader access to quality, affordable and convenient laboratory services, with a broader network of patient service centers and three rapid-response clinical laboratories in the state. Physicians in Connecticut will also be able to order testing and consult with Quest Diagnostics' medical experts at Quest's full-service clinical laboratory in Marlborough, Mass. This lab provides state-of-the-art testing services, such as next-generation sequencing and bioinformatics, to aid the detection of cancer, dementia and other diseases.

HHC's hospital-based laboratories and the inpatient and outpatient services they provide are not included in the transaction and will remain part of the HHC system. Professional consultative pathology services performed by Hartford Pathology Associates are also not part of the acquisition.

This is the fifth acquisition of a laboratory outreach service business from a hospital system by Quest Diagnostics since 2012, when the company introduced its five-point strategy, which includes restoring growth and driving disciplined capital deployment through strategically-aligned, accretive acquisitions. The company has also formed several agreements with hospitals to provide professional laboratory services, such as lab management outsourcing. Quest's scale and expertise enable it to produce highly innovative test services cost-effectively, with fees that are often far lower than those of other providers for comparable services, according to independent research.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

Quest Diagnostics Contacts: 
Wendy Bost, Quest Diagnostics (Media): 973-520-2800 
Dan Haemmerle, Quest Diagnostics (Investors): 973-520-2900

Hartford HealthCare Contact:
Rebecca Stewart, Hartford HealthCare (Media): 860-972-4285

Logo -

SOURCE Quest Diagnostics
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
2. Quest Diagnostics To Speak At The 34th Annual J.P. Morgan Healthcare Conference
3. NeuroQuest to Begin US Clinical Validation Trials for Alzheimers Blood Test
4. Global Futurist Jack Uldrich Says, "Question the Future"
5. Quest Diagnostics Increases Share Repurchase Authority by $500 Million
6. Quest Diagnostics Declares Quarterly Cash Dividend
7. Kalorama: With Alzheimers Disease, A Quest to Know More Fuels Biomarker Search
8. Quest PharmaTechs Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer
9. Ditthavong & Steiner, P.C., Has Filed a Request for Investigation of Alleged Trademark Infringement by Apple Inc.
10. Delaware Soybean Board Releases Request for Research Proposals
11. Endo Provides Informational Frequently Asked Questions & Answers
Post Your Comments:
(Date:3/10/2020)... ... , ... Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated ... a suite of extended antigen in a gel testing format used for blood phenotyping ... ORTHO VISION® Max in the United States and Canada. The clearances allow testing for ...
(Date:3/3/2020)... ... March 03, 2020 , ... Frictionless Solutions, ... medical device industries, was recognized by INC. 5,000 on an annual list of ... note industry leaders greatly impacting their spheres of influence and experiencing considerable development. ...
(Date:2/21/2020)... ... February 20, 2020 , ... In a free session ... from Synteract including Lisa Dilworth, BS, MS, Vice President Rare, Orphan and ... with feasible strategies and solutions to support patients, sites and sponsors. , When planning ...
(Date:2/19/2020)... ... 2020 , ... Shoreline Biome, a microbiome research ... recently unveiled a novel DNA isolation product. , Shoreline Rapid Prep is a ... weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB from Gram-negative bacteria, ...
Breaking Biology Technology:
(Date:3/9/2020)... DALLAS (PRWEB) , ... March ... ... by enterprises witnessed a steep growth rate of 64% last year, as ... to new research from Everest Group. Unfortunately, only 13% of all transformation ...
(Date:3/5/2020)... ... March 05, 2020 , ... In ... . The AlphaSTEM Test™ is the first, and still only, available technology ... technologies that attempt to provide information about the number and quality of therapeutic ...
(Date:3/3/2020)... LAGUNA HILLS, Calif. (PRWEB) , ... March 03, 2020 , ... ... 300 spinal levels with the dualX Expanding Interbody Fusion System. , The ... in Fresno, CA. After the case Dr. Najafi noted, “dualX has completely changed ...
Breaking Biology News(10 mins):